CCL2/MCP-1, interleukin-8, and fractalkine/CXC3CL1: Potential biomarkers of epileptogenesis and pharmacoresistance in childhood epilepsy

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F23%3A00078213" target="_blank" >RIV/00159816:_____/23:00078213 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/23:00131281 RIV/00216208:11130/23:10465690 RIV/65269705:_____/23:00078213 RIV/00064203:_____/23:10465690

Result on the web

<a href="https://www.sciencedirect.com/science/article/pii/S1090379823000910?pes=vor" target="_blank" >https://www.sciencedirect.com/science/article/pii/S1090379823000910?pes=vor</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ejpn.2023.06.001" target="_blank" >10.1016/j.ejpn.2023.06.001</a>

Result language

angličtina

Original language name

CCL2/MCP-1, interleukin-8, and fractalkine/CXC3CL1: Potential biomarkers of epileptogenesis and pharmacoresistance in childhood epilepsy

Original language description

Objective: The pathophysiological processes leading to epileptogenesis and pharmacoresistance in epilepsy have been the subject of extensive preclinical and clinical research. The main impact on clinical practice is the development of new targeted therapies for epilepsy. We studied the importance of neuroinflammation in the development of epileptogenesis and pharmacoresistance in childhood epilepsy patients.Methods: A cross-sectional study conducted at two epilepsy centers in the Czech Republic compared 22 phar-macoresistant patients and 4 pharmacodependent patients to 9 controls. We analyzed the ProcartaPlexTM 9-Plex immunoassay panel consisting of interleukin (IL)-6, IL-8, IL-10, IL-18, CXCL10/IP-10, monocyte chemoattractant protein 1 (CCL2/MCP-1), B lymphocyte chemoattractant (BLC), tumor necrosis factor-alpha (TNF-&amp; alpha;), and che-mokine (C-X3-X motif) ligand 1 (fractalkine/CXC3CL1) to determine their alterations in cerebrospinal fluid (CSF) and blood plasma, concurrently.Results: The analysis of 21 paired CSF and plasma samples in pharmacoresistant patients compared to controls revealed a significant elevation of CCL2/MCP-1 in CSF (p &lt; 0.000512) and plasma (p &lt; 0.00.017). Higher levels of fractalkine/CXC3CL1 were revealed in the plasma of pharmacoresistant patients than in controls (p &lt; 0.0704), and we determined an upward trend in CSF IL-8 levels (p &lt; 0.08). No significant differences in CSF and plasma levels were detected between pharmacodependent patients and controls.Conclusion: Elevated CCL2/MCP-1 in CSF and plasma, elevated levels of fractalkine/CXC3CL1 in CSF, and a trend toward elevated IL-8 in the CSF of patients with pharmacoresistant epilepsy indicate these cytokines as potential biomarkers of epileptogenesis and pharmacoresistance. CCL2/MCP-1was detected in blood plasma; this assess-ment may be easily achieved in clinical practice without the invasiveness of a spinal tap. However, due to the complexity of neuroinflammation in epilepsy, further studies are warranted to confirm our findings.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30210 - Clinical neurology

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

European journal of paediatric neurology

ISSN

1090-3798

e-ISSN

1532-2130

Volume of the periodical

46

Issue of the periodical within the volume

SEP 2023

Country of publishing house

GB - UNITED KINGDOM

Number of pages

7

Pages from-to

48-54

UT code for WoS article

001041297900001

EID of the result in the Scopus database

2-s2.0-85164430449